- 7/24 Live Call Center
Endocrinology focuses on hormonal system and metabolic health. Learn about the diagnosis and treatment of diabetes, thyroid disorders, and adrenal conditions.
Send us all your questions or requests, and our expert team will assist you.
Accurate diagnosis of hyperparathyroidism relies on a combination of biochemical testing and advanced imaging. Because the symptoms can be vague and overlap with other conditions, the definitive diagnosis is primarily laboratory-based. The hallmark of primary hyperparathyroidism is an inappropriate elevation of parathyroid hormone (PTH) in the presence of hypercalcemia. Once the biochemical diagnosis is established, the focus shifts to localization—identifying which of the four glands is abnormal to guide surgical intervention. This section outlines the step-by-step evaluation process, from initial blood panels to sophisticated scanning techniques, ensuring that patients are correctly stratified for treatment.
The diagnostic journey typically begins with a comprehensive metabolic panel. The finding of hypercalcemia (serum calcium > 10.2 mg/dL) should always trigger a reflex measurement of intact PTH. In a healthy individual, high calcium should suppress PTH production. Therefore, a PTH level that is high, or even “inappropriately normal,” in the setting of hypercalcemia confirms the diagnosis of primary hyperparathyroidism. It is crucial to measure calcium and PTH simultaneously to interpret the relationship correctly. Albumin levels are also checked, as calcium binds to albumin; if albumin is low, the total calcium may appear normal while the biologically active “ionized” calcium remains elevated.
Interpretation requires nuance. In classic primary hyperparathyroidism, both calcium and PTH are elevated. However, in “normocalcemic primary hyperparathyroidism,” patients exhibit constantly elevated PTH with calcium levels that hover at the upper limit of normal. This variant requires careful exclusion of secondary causes such as vitamin D deficiency or malabsorption. Conversely, in secondary hyperparathyroidism, calcium is low or normal while PTH is high. Differentiating these patterns is essential to avoid unnecessary surgery for secondary causes or missed diagnoses in subtle primary disease.
Checking 25-hydroxyvitamin D levels is a mandatory part of the workup. Vitamin D deficiency is a common cause of secondary hyperparathyroidism and can coexist with primary disease. In primary hyperparathyroidism, low vitamin D levels can mask the severity of hypercalcemia because there is less substrate for calcium absorption. Clinicians must distinguish whether the high PTH is purely a reaction to low vitamin D (secondary) or if it persists despite adequate stores. Often, vitamin D is cautiously replenished to clarify the diagnosis.
A 24-hour urine calcium collection is frequently performed to assess the kidneys’ handling of calcium and to rule out a rare genetic condition called Familial Hypocalciuric Hypercalcemia (FHH). In FHH, the kidneys and parathyroid glands have a faulty set-point for calcium sensing, leading to high blood calcium but very low urine calcium. Patients with FHH do not benefit from surgery. In contrast, patients with classic primary hyperparathyroidism typically have elevated or normal levels of urinary calcium (hypercalciuria), putting them at risk for kidney stones. This test helps stratify fracture and stone risk, influencing the decision to operate.
Once the biochemical diagnosis is secure, imaging is used solely for localization, not for diagnosis. The goal is to identify the location of the adenoma(s) to facilitate a minimally invasive surgical approach. Negative imaging does not rule out the disease; it simply means the surgeon may need to inspect all four glands during the operation. Modern imaging techniques have significantly improved the success rates of focused parathyroidectomies.
The Sestamibi scan is a nuclear medicine study and a workhorse of parathyroid localization. A radioactive tracer (Technetium-99m sestamibi) is injected intravenously. This tracer is absorbed by both thyroid and parathyroid tissue but washes out of the thyroid relatively quickly. Overactive parathyroid adenomas, which are mitochondria-rich, retain the tracer longer. Delayed images taken 2-3 hours later often show a persistent “hot spot,” revealing the location of the adenoma. SPECT/CT fusion imaging, which combines the functional scan with anatomical CT, offers even greater precision in 3D localization.
Neck ultrasound is a non-invasive, radiation-free modality used alongside Sestamibi scanning. An experienced sonographer or surgeon examines the neck to identify enlarged parathyroid glands. Ultrasound is particularly useful for detecting intrathyroidal parathyroid adenomas and assessing concomitant thyroid pathology, such as nodules, which might need to be addressed during the same surgery. It provides anatomical details that help the surgeon plan the incision and approach. However, its sensitivity is operator-dependent and may be limited in patients with short necks or multinodular goiters.
A Dual-Energy X-ray Absorptiometry (DEXA) scan is essential to evaluate the impact of the disease on skeletal health. The scan measures bone mineral density at the lumbar spine, hip, and distal radius. The distal radius is a cortical bone site that is particularly sensitive to the catabolic effects of excess PTH and is often the first site to show demineralization. The results help determine the severity of the disease; the presence of osteoporosis (T-score < -2.5) or significant osteopenia is a strong indication for surgical intervention, even in asymptomatic patients.
The differential diagnosis for hypercalcemia includes malignancy, granulomatous diseases (like sarcoidosis), and medication effects (thiazide diuretics, lithium). Malignancy-associated hypercalcemia usually presents with very high calcium levels and suppressed (low) PTH, distinguishing it from hyperparathyroidism. Thiazide diuretics reduce urinary calcium excretion and can mimic mild hyperparathyroidism; typically, the medication is paused for a few months to see if values normalize. FHH is excluded via urine testing. A thorough history and medication review are vital to rule out these other etiologies before proceeding to surgery.
In complex cases, such as re-operative surgery or when non-invasive imaging is negative, invasive localization may be required. Selective venous sampling involves threading a catheter into the neck veins to measure PTH levels draining from different areas. A “step-up” in PTH concentration localizes the hyperfunctioning gland to a specific quadrant. Four-dimensional CT (4D-CT) is another advanced imaging technique that uses the rapid wash-in and wash-out characteristics of contrast dye to visualize adenomas that might be missed by standard scans. These tools ensure that even small or ectopic glands are found.
Send us all your questions or requests, and our expert team will assist you.
The diagnosis is primarily confirmed by measuring serum calcium and parathyroid hormone (PTH) levels simultaneously. Elevated calcium combined with elevated or inappropriately normal PTH levels indicates primary hyperparathyroidism. Vitamin D and kidney function tests are also reviewed to support the diagnosis.
The 24-hour urine collection measures the total amount of calcium excreted in a day. It is critical for ruling out Familial Hypocalciuric Hypercalcemia (FHH), a genetic condition that does not require surgery. It also assesses the risk of kidney stones, which helps determine the need for treatment.
No, scans are not used to diagnose the condition; they are used to locate the abnormal gland after the diagnosis is made by blood tests. A negative scan does not mean you don’t have the disease; it just means the surgeon will need to examine all four glands during the operation.
A Sestamibi scan is a nuclear imaging test where a small amount of radioactive tracer is injected into the vein. The tracer is absorbed by the parathyroid glands. Overactive glands hold onto the tracer longer than normal tissue, allowing them to be visualized as “hot spots” on the camera, helping the surgeon find the tumor.
Yes, this is known as “normocalcemic primary hyperparathyroidism.” In this variant, patients have consistently high PTH levels but calcium levels that remain within the normal range. It is a diagnosis of exclusion, meaning other causes for high PTH like vitamin D deficiency must be ruled out first.
Your Comparison List (you must select at least 2 packages)
